Maurizio Muscaritoli

Maurizio Muscaritoli

Auto-generated profile, based on publicly available information

Maurizio Muscaritoli

Department of Clinical Medicine, Sapienza University of Rome, Rome, Italy

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 February 2020 in Journal of Parenteral and Enteral Nutrition
Verified
Journal Article
Closed access
PDF file
RMRobert G. Martindale
Robert G. Martindale
DBDavid Berlana
David Berlana
JBJoseph I. Boullata
Joseph I. Boullata
WCWei Cai
Wei Cai
PCPhilip Calder
Philip Calder
SKStanislaw Klek
Stanislaw Klek

8 May 2020 in Journal of Parenteral and Enteral Nutrition
Verified
Journal Article
Closed access
PDF file
Edoardo RosatoEdoardo Rosato
Edoardo Rosato
AGAntonietta Gigante
Antonietta Gigante
MGMaria Ludovica Gasperini
Maria Ludovica Gasperini
LPLidia Proietti
Lidia Proietti
MMMaurizio Muscaritoli
Maurizio Muscaritoli

26 July 2020 in Journal of Parenteral and Enteral Nutrition
Verified
Journal Article
Open access
PDF file
LPLorenzo AdRes PRADELLI
Lorenzo AdRes PRADELLI
SKStanislaw Klek
Stanislaw Klek
KMKonstantin Mayer
Konstantin Mayer
AAAbdul Jabbar Omar Alsaleh
Abdul Jabbar Omar Alsaleh
MRMartin D. Rosenthal
Martin D. Rosenthal
MMMaurizio Muscaritoli
Maurizio Muscaritoli
Background: ω‐3 Fatty acid (FA)–containing parenteral nutrition (PN) is associated with improvements in patient outcomes and with reductions in hospital length of stay (HLOS) vs standard PN regimens (containing non–ω‐3 FA lipid emulsions). We present a cost‐effectiveness analysis of ω‐3 FA–containing PN vs standard PN in 5 European countries (France, Germany, Italy, Spain, UK) and the US.Methods: This pharmacoeconomic model was based on estimates of ω‐3 efficacy reported in a recent meta‐analysis and data from country‐specific sources. It utilized a probabilistic discrete event simulation model to compare ω‐3 FA–containing PN with standard PN in a population of critically ill and general ward patients. The influence of model parameters was evaluated using probabilistic and deterministic sensitivity analyses.Results: Overall costs were reduced with ω‐3 FA–containing PN in all 6 countries compared with standard PN, ranging from €1741 (±€1284) in Italy to €5576 (±€4193) in the US. Expenses for infections and HLOS were lower in all countries for ω‐3 FA–containing PN vs standard PN, with the largest cost differences for both in the US (infection: €825 ± €4001; HLOS: €4879 ± €1208) and the smallest savings in the UK for infections and in Spain for HLOS (€63 ± €426 and €1636 ± €372, respectively).Conclusion: This cost‐effectiveness analysis in 6 countries demonstrates that the superior clinical efficacy of ω‐3 FA–containing PN translates into significant decreases in mean treatment cost, rendering it an attractive cost‐saving alternative to standard PN across different healthcare systems.

12 February 2020 in Journal of Parenteral and Enteral Nutrition
Verified
Journal Article
Open access
PDF file
LPLorenzo AdRes PRADELLI
Lorenzo AdRes PRADELLI
MMMaurizio Muscaritoli
Maurizio Muscaritoli
SKStanislaw Klek
Stanislaw Klek
RMRobert G. Martindale
Robert G. Martindale
The inclusion of ω‐3 fatty acids as part of parenteral nutrition is associated with clinical benefits such as a reduced likelihood of infectious complications and shorter hospital and intensive care unit (ICU) stays. As healthcare resources are limited, pharmacoeconomic analyses have been performed, typically modeling studies, using cost and outcomes data to investigate the cost‐effectiveness of parenteral nutrition regimens including ω‐3 fatty acids from fish oil compared with standard parenteral nutrition without such ω‐3 fatty acids. This review covers pharmacoeconomic studies encompassing Italian, French, German, and UK hospitals for ICU and non‐ICU hospitalized patients, and for ICU patients in China. The results show that the use of parenteral nutrition including ω‐3 fatty acids more than offsets any additional acquisition costs in all national scenarios investigated to date, indicating that parenteral nutrition including ω‐3 fatty acids is a clinically and economically beneficial strategy compared with standard parenteral nutrition.

14 August 2020 in Journal of Parenteral and Enteral Nutrition
Verified
Journal Article
Closed access
PDF file
Alessio MolfinoAlessio Molfino
Alessio Molfino
MGMaria Ludovica Gasperini
Maria Ludovica Gasperini
AGAntonietta Gigante
Antonietta Gigante
Edoardo RosatoEdoardo Rosato
Edoardo Rosato
MMMaurizio Muscaritoli
Maurizio Muscaritoli